The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Study question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective in improving metabolic associated steatotic liver disease in type 2 diabetic patients?
Epistemonikos ID: 50d40e10c50d7fe199b3c59fff9d5bb6b28ffd01
First added on: May 15, 2024